ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
Delayed Nasdaq  -  05/18 03:49:08 pm EDT
0.2935 USD   -4.55%
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
GL
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
AQ
05/09HC Wainwright Trims Eloxx Pharmaceuticals Price Target to $0.5 From $1, Maintains Neutral Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oppenheimer Initiates Coverage on Eloxx Pharmaceuticals With Outperform Rating, $4 Price Target

12/17/2021 | 10:33am EDT


ę MT Newswires 2021
All news about ELOXX PHARMACEUTICALS, INC.
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Pr..
GL
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Pr..
AQ
05/09HC Wainwright Trims Eloxx Pharmaceuticals Price Target to $0.5 From $1, Maintains Neutr..
MT
05/06ELOXX PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/06Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
04/11ELOXX PHARMACEUTICALS : April 2022 Investor Presentation
PU
04/07Top Premarket Decliners
MT
04/04ELOXX PHARMACEUTICALS : Reports Fourth Quarter 2021 Financial and Operating Results and Pr..
PU
03/31Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and P..
GL
03/31NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 1,75 M - -
Net income 2022 -43,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,61x
Yield 2022 -
Capitalization 25,4 M 25,4 M -
Capi. / Sales 2022 14,5x
Capi. / Sales 2023 15,7x
Nbr of Employees 28
Free-Float 87,3%
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,29 $
Average target price 2,88 $
Spread / Average Target 880%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial & Accounting Officer
Tomer Kariv Chairman
Vijay Modur Head-Research & Development
Ali Hariri Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-58.44%27
GILEAD SCIENCES, INC.-12.93%79 248
REGENERON PHARMACEUTICALS, INC.4.38%71 927
VERTEX PHARMACEUTICALS14.91%66 967
WUXI APPTEC CO., LTD.-18.77%42 682
BIONTECH SE-38.01%38 834